Maryam Yazdy: Promising New Therapy for Patients With CLL/SLL
Maryam Yazdy, Senior Medical Director of Clinical Development at BeOne Medicines, shared a post on LinkedIn:
“Just completed a fantastic investigators meeting in São Paulo for the CaDAnCe-302 study: BTK degrader (BGB-16673) vs Investigator’s Choice.
It was a pleasure to engage in thoughtful and informative discussions with the investigators and research teams from Brazil and Argentina along with the BeOne team. I appreciated learning about the local health systems and the shared commitment to advancing care.
BeOne Medicines BTK degrader (BGB-16673) is a promising new therapy for patients with CLL/SLL who have received multiple prior lines of treatment. We hope this study will bring new treatment options and renewed hope for patients—our collective mission in drug development.”
More posts featuring Maryam Yazdy.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023